Articles by Trisha Gladd

1. Merck's Path To Continuous Manufacturing For Solid Oral Dose Products: What Stands In The Way? 12/8/2016

   As the evolution of the global pharmaceutical industry continues to drive the need for more flexibility and lower costs, continuous manufacturing becomes an even more appealing and sensible option. However, despite the tremendous promise of its economic and quality control benefits, there are still many concerns about the regulatory landscape for continuous manufacturing. Dr. Christine Moore, executive director and global head of chemistry, manufacturing and control (CMC) policy at Merck, recently discussed the company’s pursuit of worldwide approval of continuous manufacturing for solid oral dosage products and what regulatory risks it sees as potential roadblocks.

2. Taking The Guesswork Out Of Drug Development 8/1/2016

   As NIH funding has decreased and the cost of conducting biomedical research has gone up, highly trained scientists with potentially groundbreaking ideas are left with no outlet to commercialize their idea.

3. 5 Manufacturing Trends Aimed To Support The Biologics Boom 12/1/2015

   The changes in technologies, processes, and relationships you can expect in 2016 to support the expected dramatic increase in the use of biologics.

4. What Industry Trends In Biotherapeutic Manufacturing Tell Us About The Next 10 Years 10/2/2014

   When considering the topic he would present at the 11th Annual BioProcess International Conference & Exhibition, Ralph Lambalot, VP of biologics development at AbbVie, thought this year’s event would be a good milestone to look back at how far the industry has come in the past 10 years and what we can infer from the decade’s trends about where innovation will go in the next 10 years.